The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hosseinkhani, H., & Tabata, Y. (2004) · Journal of Controlled Release · doi:10.1016/s0168-3659(04)00102-6 · Cited by 39
RetractedPierschbacher, M. D., & Ruoslahti, E. (1984) · Nature · doi:10.1038/309030a0 · Cited by 3,658
Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment
Wickham, T. J., Mathias, P., Cheresh, D. A., & Nemerow, G. R. (1993) · Cell · doi:10.1016/0092-8674(93)90231-e · Cited by 2,199
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Anti-cancer activity of targeted pro-apoptotic peptides
Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., et al. (1999) · Nature Medicine · doi:10.1038/12469 · Cited by 936
Schiffelers, R. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh140 · Cited by 901
Self-citationTumor Regression by Targeted Gene Delivery to the Neovasculature
Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002) · Science · doi:10.1126/science.1070200 · Cited by 858
Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., & Li, K. C. P. (1998) · Nature Medicine · doi:10.1038/nm0598-623 · Cited by 850
N -Methylated Cyclic RGD Peptides as Highly Active and Selective α V β 3 Integrin Antagonists
Dechantsreiter, M. A., Planker, E., Mathä, B., Lohof, E., Hölzemann, G., Jonczyk, A., Goodman, S. L., & Kessler, H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm970832g · Cited by 838
Grant, D. S., Tashiro, K.-I., Segui-Real, B., Yamada, Y., Martin, G. R., & Kleinman, H. K. (1989) · Cell · doi:10.1016/0092-8674(89)90945-8 · Cited by 740
Pierschbacher, M. D., & Ruoslahti, E. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45376-8 · Cited by 649
Haubner, R., Wester, H. J., Weber, W., Mang, C., Ziegler, S. I., Goodman, S. L., Senekowitsch–Schmidtke, R., Kessler, H., & Schwaiger, M. (2001) · PubMed · Cited by 563
Haubner, R., Weber, W. A., Beer, A. J., Vabuliene, E., Reim, D., Sarbia, M., Becker, K.-F., Goebel, M., Hein, R., Wester, H.-J., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020070 · Cited by 489
Wickham, T. J., Tzeng, E., Shears, L. L., Roelvink, P. W., Li, Y., Lee, G. M., Brough, D. E., Lizonova, A., & Kovesdi, I. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8221-8229.1997 · Cited by 488
Koivunen, E., Wang, B., & Ruoslahti, E. (1995) · Nature Biotechnology · doi:10.1038/nbt0395-265 · Cited by 477
Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors.
Lawler, J., Weinstein, R., & Hynes, R. O. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.6.2351 · Cited by 474
Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 471
Ganly, I., Kirn, D. H., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C. C., et al. (2000) · PubMed · Cited by 432
Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., & Corti, A. (2000) · Nature Biotechnology · doi:10.1038/81183 · Cited by 419
Eggermont, A. M., Schraffordt Koops, H., Liénard, D., Kroon, B. B., van Geel, A. N., Hoekstra, H. J., & Lejeune, F. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2653 · Cited by 398
Eliceiri, B. P., Klemke, R., Strömblad, S., & Cheresh, D. A. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.5.1255 · Cited by 396
Miyauchi, A., Alvarez, J., Greenfield, E. M., Teti, A., Grano, M., Colucci, S., Zambonin-Zallone, A., Ross, F. P., Teitelbaum, S. L., & Cheresh, D. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54932-2 · Cited by 393
Haubner, R., Wester, H. J., Burkhart, F., Senekowitsch–Schmidtke, R., Weber, W., Goodman, S. L., Kessler, H., & Schwaiger, M. (2001) · PubMed · Cited by 381
Winter, P. M., Caruthers, S. D., Kassner, A., Harris, T. D., Chinen, L. K., Allen, J. S., Lacy, E. K., Zhang, H., Robertson, J. D., Wickline, S. A., et al. (2003) · PubMed · Cited by 371
Structure of a major immunogenic site on foot-and-mouth disease virus
Logan, D., Abu-Ghazaleh, R., Blakemore, W., Curry, S., Jackson, T., King, A., Lea, S., Lewis, R., Newman, J., Parry, N., et al. (1993) · Nature · doi:10.1038/362566a0 · Cited by 366
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
Haubner, R., Wester, H., Reuning, U., Senekowitsch–Schmidtke, R., Diefenbach, B., Kessler, H., Stöcklin, G., & Schwaiger, M. (1999) · PubMed · Cited by 356
Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G. N., Khan, A., Conrad, C. A., Liu, T.-J., Jiang, H., Lemoine, M. G., Suzuki, K., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.652 · Cited by 350
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen, M. L., Oyen, W. J. G., Dijkgraaf, I., Massuger, L. F. A. G., Frielink, C., Edwards, D. S., Rajopadhye, M., Boonstra, H., Corstens, F. H. M., & Boerman, O. C. (2002) · PubMed · Cited by 331
Wu, Y., Zhang, X., Xiong, Z., Cheng, Z., Fisher, D. R., Liu, S., Gambhir, S. S., & Chen, X. S. (2005) · PubMed · Cited by 325
Identification of the Integrin VLA-2 as a Receptor for Echovirus 1
Bergelson, J. M., Shepley, M. P., Chan, B. M. C., Hemler, M. E., & Finberg, R. W. (1992) · Science · doi:10.1126/science.1553561 · Cited by 319
Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin
Schiffelers, R. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00240-2 · Cited by 310
Self-citationLeininger, E., Roberts, M., Kenimer, J. G., Charles, I. G., Fairweather, N., Novotny, P., & Brennan, M. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.345 · Cited by 296
Magnetic resonance contrast enhancement of neovasculature with ?v?3-targeted nanoparticles
Anderson, S. A., Rader, R. K., Westlin, W. F., Null, C., Jackson, D., Lanza, G. M., Wickline, S. A., & Kotyk, J. J. (2000) · Magnetic Resonance in Medicine · doi:10.1002/1522-2594(200009)44:3<433::aid-mrm14>3.0.co;2-9 · Cited by 271
Thumshirn, G., Hersel, U., Goodman, S. L., & Kessler, H. (2003) · Chemistry – A European Journal · doi:10.1002/chem.200204304 · Cited by 269
Chen, X., Park, R., Tohme, M., Shahinian, A. H., Bading, J. R., & Conti, P. S. (2004) · Bioconjugate Chemistry · doi:10.1021/bc0300403 · Cited by 260
Beer, A. J., Haubner, R., Goebel, M., Luderschmidt, S., Spilker, M. E., Wester, H., Weber, W., & Schwaiger, M. (2005) · PubMed · Cited by 258
Chen, X., Plasencia, C., Hou, Y., & Neamati, N. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049165z · Cited by 256
Chen, X. S., Hou, Y., Tohme, M. S., Park, R. J.-H., Khankaldyyan, V., Gonzales-Gomez, I., Bading, J. R., Laug, W. E., & Conti, P. S. (2004) · PubMed · Cited by 254
Molecular MR imaging of melanoma angiogenesis with ανβ3‐targeted paramagnetic nanoparticles
Schmieder, A. H., Winter, P. M., Caruthers, S. D., Harris, T. D., Williams, T. A., Allen, J. S., Lacy, E. K., Zhang, H., Scott, M. J., Hu, G., et al. (2005) · Magnetic Resonance in Medicine · doi:10.1002/mrm.20391 · Cited by 246
Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway
Erbacher, P., Remy, J.-S., & Behr, J.-P. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300783 · Cited by 236
Kim, B., Tang, Q., Biswas, P. S., Xu, J., Schiffelers, R. M., Xie, F. Y., Ansari, A. M., Scaria, P. V., Woodle, M. C., Lu, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63267-1 · Cited by 234
Self-citationIntegrin targeting using RGD‐PEI conjugates for in vitro gene transfer
Kunath, K., Merdan, T., Hegener, O., Häberlein, H., & Kissel, T. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.382 · Cited by 231
Interaction of West Nile Virus with αvβ3 Integrin Mediates Virus Entry into Cells
Chu, J. J.-H., & Ng, M.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410208200 · Cited by 227
Fromm, J. R., Hileman, R. E., Caldwell, E. E. O., Weiler, J. M., & Linhardt, R. J. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.9963 · Cited by 225
The Toxicology of Interleukin-12: A Review
Car, B. D., Eng, V. M., Lipman, J. M., & Anderson, T. D. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700112 · Cited by 220
MicroPET imaging of breast cancer ?-integrin expression with Cu-labeled dimeric RGD peptides
CHEN, X., LIU, S., HOU, Y., TOHME, M., PARK, R., BADING, J., & CONTI, P. (2004) · Molecular Imaging & Biology · doi:10.1016/j.mibio.2004.06.004 · Cited by 212
18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis
Chen, X., Park, R., Shahinian, A. H., Tohme, M., Khankaldyyan, V., Bozorgzadeh, M. H., Bading, J. R., Moats, R., Laug, W. E., & Conti, P. S. (2004) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2003.10.002 · Cited by 212
Roivainen, M., Piirainen, L., Hovi, T., Virtanen, I., Riikonen, T., Heino, J., & Hyypiä, T. (1994) · Virology · doi:10.1006/viro.1994.1494 · Cited by 210
Solution stability of linear vs. cyclic RGD peptides
Bogdanowich‐Knipp, S. J., Chakrabarti, S., Siahaan, T. J., Williams, T. D., & Dillman, R. K. (1999) · The Journal of Peptide Research · doi:10.1034/j.1399-3011.1999.00052.x · Cited by 206
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation
Chen, X., Park, R., Shahinian, A. H., Bading, J. R., & Conti, P. S. (2004) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2003.07.003 · Cited by 203
Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins
Goodman, S. L., Hölzemann, G., Sulyok, G. A. G., & Kessler, H. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0102598 · Cited by 196
Binding and internalization of microorganisms by integrin receptors
Isberg, R. R., & Tran Van Nhieu, G. (1994) · Trends in Microbiology · doi:10.1016/0966-842x(94)90338-7 · Cited by 193
The RGD story: a personal account
Ruoslahti, E. (2003) · Matrix Biology · doi:10.1016/s0945-053x(03)00083-0 · Cited by 189
Lamfers, M. L. M., Grill, J., Dirven, C. M. F., van Beusechem, V. W., Geoerger, B., Berg, J. V. D., Alemany, R., Fueyo-Margareto, J., Curiel, D. T., Vassal, G., et al. (2002) · PubMed · Cited by 183
Comparison of a Monomeric and Dimeric Radiolabeled RGD-Peptide for Tumor Targeting
Janssen, M., Oyen, W. J. G., Massuger, L. F. A. G., Frielink, C., Dijkgraaf, I., Edwards, D. S., Radjopadhye, M., Corstens, F. H. M., & Boerman, O. C. (2002) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497802320970244 · Cited by 174
Reynolds, P. N., Dmitriev, I. P., & Curiel, D. T. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300941 · Cited by 170
Targeting tumor angiogenic vasculature using polymer–RGD conjugates
Mitra, A., Mulholland, J., Nan, A., McNeill, E., Ghandehari, H., & Line, B. R. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.09.023 · Cited by 162
Micro-PET Imaging of αvβ3-Integrin Expression with 18F-Labeled Dimeric RGD Peptide
Chen, X., Tohme, M., Park, R., Hou, Y., Bading, J. R., & Conti, P. S. (2004) · Molecular Imaging · doi:10.1162/1535350041464892 · Cited by 159
Kirn, D. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.3.525 · Cited by 159
Pytela, R. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02953.x · Cited by 158
MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide
Chen, X. S., Park, R. J.-H., Hou, Y., Khankaldyyan, V., Gonzales-Gomez, I., Tohme, M. S., Bading, J. R., Laug, W. E., & Conti, P. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1452-2 · Cited by 158
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.
Bauerschmitz, G. J., Lam, J. T., Kanerva, A., Suzuki, K., Nettelbeck, D. M., Dmitriev, I. P., Krasnykh, V. N., Mikheeva, G., Barnes, M. N., Alvarez, R. D., et al. (2002) · PubMed · Cited by 157
Solution Structures and Integrin Binding Activities of an RGD Peptide with Two Isomers
Assa‐Munt, N., Jia, X., Laakkonen, P. M., & Ruoslahti, E. I. (2001) · Biochemistry · doi:10.1021/bi002101f · Cited by 157
Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins
Mahmood, I., & Green, M. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544040-00001 · Cited by 150
Kok, R. J., Schraa, A. J., Bos, E. J., Moorlag, H. E., Ásgeirsdóttir, S. A., Everts, M., Meijer, D. K. F., & Molema, G. (2001) · Bioconjugate Chemistry · doi:10.1021/bc015561+ · Cited by 146
Self-citationLiposomes Modified with Cyclic RGD Peptide for Tumor Targeting
Dubey, P. K., Mishra, V., Jain, S., Mahor, S., & Vyas, S. P. (2004) · Journal of drug targeting · doi:10.1080/10611860410001728040 · Cited by 144
Coupling Tumor Necrosis Factor-α with αV Integrin Ligands Improves Its Antineoplastic Activity
Curnis, F., Gasparri, A. M., Sacchi, A., Longhi, R., & Corti, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1753 · Cited by 138
Xiong, X.-B., Huang, Y., Lü, W.-L., Zhang, X., Zhang, H., Nagai, T., & Zhang, Q. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20397 · Cited by 134
Bibby, D. C., Talmadge, J. E., Dalal, M. K., Kurz, S. G., Chytil, K. M., Barry, S. E., Shand, D. G., & Steiert, M. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.12.021 · Cited by 133
Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector.
Kasono, K., Blackwell, J. L., Douglas, J. T., Dmitriev, I. P., Strong, T. V., Reynolds, P. N., Kropf, D. A., Carroll, W. R., Peters, G. E., Bucy, R. P., et al. (1999) · PubMed · Cited by 133
Highly branched HK peptides are effective carriers of siRNA
Leng, Q., Scaria, P. V., Zhu, J., Ambulos, N. P., Campbell, P., & Mixson, A. J. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.748 · Cited by 133
Ogawara, K., Rots, M. G., Kok, R. J., Moorlag, H. E., van Loenen-Weemaes, A. M., Meijer, D. K. F., Haisma, H. J., & Molema, G. (2004) · Human Gene Therapy · doi:10.1089/10430340460745766 · Cited by 129
Self-citationHölig, P., Bach, M., Völkel, T., Nahde, T., Hoffmann, S., Müller, R., & Kontermann, R. E. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh055 · Cited by 129
Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis
Kim, W. J., Yockman, J. W., Lee, M., Jeong, J. H., Kim, Y., & Kim, S. W. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.04.016 · Cited by 126
Hemminki, A., Belousova, N., Zinn, K. R., Liu, B., Wang, M., Chaudhuri, T. R., Rogers, B. E., Buchsbaum, D. J., Siegal, G. P., Barnes, M. N., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0446 · Cited by 125
An Angiogenic, Endothelial-Cell-Targeted Polymeric Gene Carrier
Suh, W., Han, S., Yu, L., & KIM, S. (2002) · Molecular Therapy · doi:10.1016/s1525-0016(02)90721-5 · Cited by 124
Ganly, I., Eckhardt, S. G., Rodriguez, G. I., et al. (2000) · Clinical Cancer Research · Cited by 123
Albinsson, B., & Kidd, A. H. (1999) · Virus Research · doi:10.1016/s0168-1702(99)00087-8 · Cited by 115
Suzuki, K., Alemany, R., Yamamoto, M., & Curiel, D. T. (2002) · PubMed · Cited by 106
Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature
Gerlag, D. M., Borges, E., Tak, P. P., Ellerby, H. M., Bredesen, D. E., Pasqualini, R., Ruoslahti, E. I., & Firestein, G. S. (2001) · Arthritis Research & Therapy · doi:10.1186/ar327 · Cited by 106
Mizuguchi, H., Koizumi, N., Hosono, T., Ishii‐Watabe, A., Uchida, E., Utoguchi, N., Watanabe, Y., & Hayakawa, T. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301701 · Cited by 106
Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication
Marcinkiewicz, C. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381765 · Cited by 102
Roles of tumor necrosis factor p55 and p75 receptors in TNF-α-induced vascular permeability
Ferrero, E., Zocchi, M. R., Magni, E., Panzeri, M. C., Curnis, F., Rugarli, C., Ferrero, M. E., & Corti, A. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.281.4.c1173 · Cited by 99
Bai, M., Campisi, L., & Freimuth, P. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.5925-5932.1994 · Cited by 96
Targeted Delivery of IFNγ to Tumor Vessels Uncouples Antitumor from Counterregulatory Mechanisms
Curnis, F., Gasparri, A. M., Sacchi, A., Cattaneo, A., Magni, F., & Corti, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4282 · Cited by 95
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
GLADEBENDER, J., COONEY, E., KANDEL, J., & Yamashiro, D. J. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.09.001 · Cited by 87
RNA interference may be more potent than antisense RNA in human cancer cell lines
Aoki, Y., Cioca, D., Oidaira, H., et al. (2003) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2003.03801.x · Cited by 86
de Groot, F. M. H., Broxterman, H. J., Adams, H. P. H. M., van Vliet, A., TESSER, G. I., Elderkamp, Y. W., Schraa, A. J., Kok, R. J., Molema, G., Pinedo, H. M., et al. (2002) · PubMed · Cited by 86
Self-citationAnti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives
Eichhorn, M., Strieth, S., & Dellian, M. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.03.001 · Cited by 84
Modified branched peptides with a histidine-rich tail enhance in vitro gene transfection
Leng, Q. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni040 · Cited by 82
Harris, T. D., Kalogeropoulos, S., Nguyen, T., Liu, S., Bartis, J., Ellars, C. E., Edwards, S., Onthank, D. C., Silva, P., Yalamanchili, P., et al. (2003) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497803322287727 · Cited by 82
Peptide-targeted PEG-liposomes in anti-angiogenic therapy
Janssen, A. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00682-8 · Cited by 79
Davydova, J., Le, L. P., Gavrikova, T. A., Wang, M., Krasnykh, V. N., & Yamamoto, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0064 · Cited by 77
Hong, S. S., & Boulanger, P. A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00153.x · Cited by 76
Xiong, X.-B., Huang, Y., Lü, W.-L., Zhang, H., Zhang, X., & Zhang, Q. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-4588-x · Cited by 76
Knudsen, K. A., Tuszynski, G. P., Huang, T., & Niewiarowski, S. (1988) · Experimental Cell Research · doi:10.1016/0014-4827(88)90346-1 · Cited by 74
Schraa, A. J., Kok, R. J., Moorlag, H. E., Bos, E. J., Proost, J. H., Meijer, D. K. F., de Leij, L. F. M. H., & Molema, G. (2002) · International Journal of Cancer · doi:10.1002/ijc.10727 · Cited by 73
Self-citationDoxorubicin-formaldehyde conjugates targeting alphavbeta3 integrin.
Burkhart, D. J., Kalet, B. T., Coleman, M. P., Post, G. C., & Koch, T. H. (2004) · PubMed · Cited by 69
Witlox, A. M. A., van Beusechem, V. W., Molenaar, B., Bras, H., Schaap, G. R., Alemany, R., Curiel, D. T., Pinedo, H. M., Wuisman, P. I. J. M., & Gerritsen, W. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0609-03 · Cited by 66
Structure-Function Correlations of Snake Venom Disintegrins&#
Calvete, J. J. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381783 · Cited by 64
Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin
Burkhart, D. J., Kalet, B. T., Coleman, M. P., Post, G. C., & Koch, T. H. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1593.3.12 · Cited by 64
Dickerson, E. B., Akhtar, N., Steinberg, H. N., Wang, Z., Lindstrom, M. J., Padilla, M. L., Auerbach, R., & Helfand, S. C. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.663.2.12 · Cited by 64
Schraa, A. J., Kok, R. J., Berendsen, A. D., Moorlag, H. E., Bos, E. J., Meijer, D. K. F., de Leij, L. F. M. H., & Molema, G. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00206-7 · Cited by 63
Self-citationHu, P., Yan, J., Sharifi, J., Bai, T., Khawli, L. A., & Epstein, A. L. (2003) · PubMed · Cited by 62
Sterically stabilized polyplex: ligand-mediated activity
Woodle, M. C., Scaria, P. V., Ganesh, S., Subramanian, K., Titmas, R. C., Cheng, C., Yang, J., Pan, Y., Weng, K., Gu, C., et al. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00339-x · Cited by 62
Matsumoto, T. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2003.10.019 · Cited by 61
Dickerson, E. B., Akhtar, N., Steinberg, H. N., Wang, Z. Y., Lindstrom, M. J., Padilla, M. L., Auerbach, R., & Helfand, S. C. (2004) · PubMed · Cited by 57
Zarovni, N., Monaco, L., & Corti, A. (2004) · Human Gene Therapy · doi:10.1089/104303404322959524 · Cited by 55
Onthank, D. C., Liu, S., Silva, P. J., Barrett, J. A., Harris, T. D., Robinson, S. P., & Edwards, D. S. (2004) · Bioconjugate Chemistry · doi:10.1021/bc034108q · Cited by 53
Zhu, Z. B., Makhija, S. K., Lu, B., Wang, M., Rivera, A., Kim‐Park, S., Ulasov, I. V., Zhou, F., Alvarez, R. D., Siegal, G., et al. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.1.237 · Cited by 48
Targeting of Lipid-Protamine-DNA (LPD) Lipopolyplexes Using RGD Motifs
Harvie, P., Dutzar, B., Galbraith, T., Cudmore, S., O’Mahony, D. J., Anklesaria, P. N., & Paul, R. W. (2003) · Journal of Liposome Research · doi:10.1081/lpr-120026389 · Cited by 48
Haubner, R., Bruchertseifer, F., Bock, M. J., Kessler, H., Schwaiger, M., & Wester, H. J. (2004) · PubMed · doi:10.1267/nukl04010026 · Cited by 47
Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors
Borovjagin, A. V., Krendelchtchikov, A., Ramesh, N., et al. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700806 · Cited by 45
Mizuguchi, H., & Hayakawa, T. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700440 · Cited by 44
Aoki, Y., Hosaka, S., Kawa, S., & Kiyosawa, K. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700362 · Cited by 44
Highly efficient transduction of endothelial cells by targeted artificial virus-like particles
Müller, K., Nahde, T., Fahr, A., Müller, R., & Brüsselbach, S. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700280 · Cited by 44
Nonviral gene delivery systems: From simple transfection agents to artificial viruses
Mastrobattista, E., Bravo, S. A., van der Aa, M. A. E. M., & Crommelin, D. J. A. (2005) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2005.04.002 · Cited by 34
Li, J., Ji, J., Holmes, L. M., Burgin, K. E., Barton, L. B., Yu, X., Wagner, T. E., & Wei, Y. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700707 · Cited by 34
Peptide-mediated Gene Transfer of Cationic Lipid/Plasmid DNA Complexes to Endothelial Cells
Anwer, K., Kao, G., Rolland, A. P., Driessen, W. H. P., & Sullivan, S. M. (2004) · Journal of drug targeting · doi:10.1080/10611860410001724468 · Cited by 30
HIV-Tat dependent chemotaxis and invasion, key aspects of Tat mediated pathogenesis
Venè, R., Benelli, R., Noonan, D. M., & Albini, A. (2000) · Clinical & Experimental Metastasis · doi:10.1023/a:1011991906685 · Cited by 27
Molecular Organization of Protein–DNA Complexes for Cell-Targeted DNA Delivery
Arı́s, A., & Villaverde, A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3824 · Cited by 27
Nahde, T., M�ller, K., Fahr, A., et al. (2001) · The Journal of Gene Medicine · doi:10.1002/jgm.203 · Cited by 25
Nagi, P. A., Vickers, S. M., Davydova, J., Adachi, Y., Takayama, K., Barker, S., Krasnykh, V. N., Curiel, D. T., & Yamamoto, M. (2003) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(02)00437-7 · Cited by 24
A NEW COLLOIDAL LIPIDIC SYSTEM FOR GENE THERAPY
Fahr, A., Müller, K., Nahde, T., Müller, R., & Brüsselbach, S. (2002) · Journal of Liposome Research · doi:10.1081/lpr-120004774 · Cited by 19
Kuroda, K., Miyata, K., Tsutsumi, Y. M., Tsunoda, S., Nishimura, K., Mitsuishi, Y., Nakagawa, S., & Mayumi, T. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00860.x · Cited by 12
A novel Mutein of TNFα Containing the Arg‐Gly‐Asp Sequence Shows Reduced Toxicity in Intestine
Shikama, H., Miyata, K., Sakae, N., Kuroda, K., Nishimura, K., Yotsuya, S., & Kato, M. G. (1994) · Mediators of Inflammation · doi:10.1155/s096293519400013x · Cited by 11
Miyata, K., Mitsuishi, Y., SHIKAMA, H., Kuroda, K., Nishimura, K., Sakae, N., & Kato, M. G. (1995) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1995.15.161 · Cited by 10
Novel Mutein of Tumor Necrosis Factor α (F4614) with Reduced Hypotensive Effect
SHIKAMA, H., Miyata, K., Sakae, N., Mitsuishi, Y., Nishimura, K., Kuroda, K., & Kato, M. G. (1995) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1995.15.677 · Cited by 10
Cited by
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Metadata
- Authors
- Temming, K., Schiffelers, R. M., Molema, G., & Kok, R. J.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 8
- Issue
- 6
- Pages
- 381-402
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2121357123
- Cited by
- 467
- References
- 128
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.